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Gene expression profiling revealed ADAM9 to be distinctly overexpressed in pancreatic ductal adenocarcinoma (PDAC). We
examined the relevance of ADAM9 expression in PDAC diagnosis and prognosis. A total of 59 infiltrating PDACs, 32 specimens
from patients with chronic pancreatitis, 11 endocrine tumours and 24 acinar cell carcinomas were immunohistochemically analysed
for ADAM9 expression. Staining for ADAM9 was detected in 58 out of 59 (98.3%) PDACs and in two out of 24 (8.3%) acinar cell
carcinomas, but not in endocrine tumours. In the non-neoplastic pancreas, whether normal or chronically inflamed, ADAM9 was
expressed in centroacinar and intralobular duct cells, but not in interlobular duct cells and their hyperplastic lesions. Pancreatic ductal
adenocarcinomas showing cytoplasmic ADAM9 expression correlated with poor tumour differentiation and also with shorter overall
survival than in cases showing only an apical membranous staining pattern (P¼0.001). Multivariate analysis identified cytoplasmic
ADAM9 expression as an independent marker of shortened survival in a set of 42 curatively (R0) resected PDAC (Po0.05, hazard
ratio 2.85, 95% confidence interval: 1.21–6.71). The results show that ADAM9 expression distinguishes PDACs from other solid
pancreatic tumours. In addition, cytoplasmic ADAM9 overexpression is associated with poor differentiation and shortened survival.
Therefore, ADAM9 overexpression might contribute to the aggressiveness of PDACs.
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Pancreatic ductal adenocarcinoma (PDAC) is an important cause
of malignancy-related death. In the US it ranks fifth among the
leading causes of cancer death, accounting for approximately
30000 deaths annually (Jemal et al, 2003). Apart from surgery,
there is no effective therapy and even resected patients frequently
die within 1 year of the operation. In the past years, several genes
have been identified as related to the development of PDAC
(Hruban et al, 1998; Slebos et al, 2000). However, considering the
complexity of the genome, it is most likely that most of the
molecular changes causing PDAC still need to be elucidated
(Bardeesy and DePinho, 2002). Moreover, there is still a need for
prognostic markers in this devastating cancer disease.
Recently, others and we identified ADAM9 as one of the genes
that is overexpressed in PDAC, when compared to normal
pancreatic tissue using DNA microarray transcript profiling. This
result was validated by an RT–PCR analysis in PDAC cell lines,
which revealed ADAM9 expression in 13 of the 20 cell lines, and by
immunohistochemistry in a small set of PDACs (Grutzmann et al,
2003; Iacobuzio-Donahue et al, 2003). ADAM9 overexpression was
also demonstrated in prostate, breast and liver cell carcinomas
(McCulloch et al, 2000; Le Pabic et al, 2003; O’Shea et al, 2003).
ADAM9 is a member of the large ADAM family of proteases, which
are type I transmembrane proteins with both metalloproteinase
and disintegrin-containing extracellular domains. The ADAMs are
implicated in the proteolytic processing of membrane-bound TNFa
precursors and are involved in modulating cell–cell and cell–
matrix interactions (Amour et al, 2002).
Although at present the precise molecular and biological
mechanisms of ADAM9 remain to be elucidated, ADAM9 may be
involved in the carcinogenesis of PDAC. For this reason, we were
interested in determining whether the proposed differential
expression of ADAM9 in PDAC at the RNA level could be
confirmed at the protein level as well. Moreover, if possible, we
wanted to evaluate the prognostic significance of ADAM9
expression in PDACs. In this study, we demonstrate that ADAM9
expression distinguishes PDACs from pancreatic acinar cell
carcinomas and endocrine tumours. In addition, the cytoplasmic
expression of ADAM9 has a prognostic potential.
MATERIAL AND METHODS
Patients and tissues
Formalin-fixed, paraffin-embedded tissue blocks were obtained
from surgical specimens from 59 patients (mean age 59 years;
range 31–76) with PDAC, who were operated at the Department of
Visceral, Thoracic and Vascular Surgery, University Hospital Carl
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yGustav Carus, Technical University of Dresden, between 1996 and
2001. All PDAC patients received standard surgical therapy based
on their clinical stages. In addition, tissue samples were obtained
from surgical specimens from 32 patients with chronic pancrea-
titis, 11 patients with pancreatic endocrine tumours and 24
patients with acinar cell carcinomas. These tissues were selected
from the institutional files and consultation files of the Department
of Pathology, University of Kiel. Five patients with pancreatic
endocrine tumours, one patient with acinar cell carcinoma and all
32 patients with chronic pancreatitis were operated at the
Department of General Surgery and Thoracic Surgery, University
of Kiel, between 1994 and 2002. All patients were randomly
selected without stratification for known preoperative or patholo-
gical prognostic factors. The PDACs were staged (TNM classifica-
tion) and reclassified histologically (JL, GK) according to the WHO
classification (Kloppel et al, 2000). The clinicopathological features
of the PDACs are listed in Table 1.
Immunohistochemistry
Sections (4mm) were cut from formalin-fixed, paraffin-embedded
pancreatic tissue. The sections were mounted on superfrost
slides (Menzel Gla ¨ser, Braunschweig, Germany), dewaxed with
xylene and were gradually hydrated. Antigen was exposed
by heating the sections under high pressure in Tris–EDTA–
citrate buffer for 3min. The primary goat polyclonal anti-mouse
ADAM9 antibody (AF949, R&D Systems, Wiesbaden, Germany),
which crossreacts with human ADAM9, was diluted (15mgml
 1)i n
PBS containing 2% horse serum (Vector Laboratories, Burlingame,
CA, USA). After incubation for 45min, the reaction was detected
with a biotinylated anti-goat antibody (5mgml
 1, Vector Labora-
tories) and avidin–biotin–peroxidase (ABC ELITE, Vector La-
boratories). Diaminobenzidine served as chromogen. Afterwards,
the slides were briefly counterstained with haematoxylin. For the
negative control, the primary antibody was omitted. The staining
intensity was evaluated semiquantitatively as negative, weak,
moderate or strong. The final results, however, were recorded as
positive (weak, moderate or strong staining) or negative staining
only. In addition, the staining pattern was evaluated and a
distinction was made between labelling of the luminal (apical) cell
membrane of tumour cells forming glandular structures, the
basolateral cell membrane and the cytoplasm. The staining was
evaluated independently by two pathologists, who were unaware of
patient survival.
Statistical analysis
The Mantel–Haenszel test was used to assess the correlation
between the clinicopathological findings and ADAM9 expression.
For the survival analysis, a univariate analysis of 59 patients with
PDAC was performed using the Kaplan–Meier method, Mantel–
Haenszel estimation of the hazard ratios and log-rank tests for
comparing between the strata (Peto et al, 1977). The histological
grade, pTNM stage, R (residual tumour) stage and UICC stage were
evaluated in a multivariate analysis using the Cox proportional
regression hazard model. The differences at Po0.05 were
considered significant. For statistical evaluation, the SAS/STAT
software version 8 and SPSS software v. 11.0.1 were used.
RESULTS
ADAM9 immunostaining
Immunohistochemically, 58 of the 59 PDACs were positive for
ADAM9 (Table 1, Figure 1A). In 57 of the 59 PDACs, there was
staining of the luminal cell membrane in areas with glandular
Table 1 ADAM9 expression patterns in pancreatic ductal adenocarcinomas (PDAC) correlated with clinicopathological variables
ADAM9 expression Luminal ADAM9 Basolateral ADAM9 Cytoplasmic ADAM9
Total no. of patients +   +   +   +  
PDAC 59 58 1 57 2 32 27 17 42
Histological grade
G1/2 33 32 1 32 1 9 18 4 29
G3 26 26 0 25 1 23 3 13 13
Tumour stage
pT
pT1 1 1 0 1 0 0 1 0 1
pT2 6 6 0 6 0 4 2 2 4
pT3 47 46 1 45 2 25 22 12 35
pT4 5 5 0 5 0 3 2 3 2
pN
pN0 23 22 1 21 2 12 11 6 17
pN1 36 36 0 36 0 20 16 11 25
pM
pM0 52 51 1 2 50 30 22 5 37
pM1 7 7 0 0 7 2 5 2 15
Residual tumour
R0 42 41 1 2 40 27 15 13 29
R1 12 12 0 0 12 4 8 2 10
R2 5 5 0 0 5 1 4 2 3
UICC stage
13 3 0 3 0 1 2 2 2
21 6 1 5 1 1 9 2 1 1 8 3 3
3 25 25 0 25 0 15 10 7 7
4a 6 6 0 6 0 4 2 4 4
4b 6 6 0 6 0 1 5 1 1
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side of the cell was accompanied by basolateral membrane
staining. In 17 tumours, there was additionally strong cytoplasmic
staining (Table 1, Figure 1B–D). Adjacent non-neoplastic pan-
creatic tissue as well as chronically inflamed pancreatic tissue
showed weak ADAM9 expression along the luminal membrane of
intralobular duct cells and centroacinar cells (Figure 1E and F).
Hyperplastic and proliferative duct lesions (i.e. pancreatic
intraepithelial neoplasiaFigure 1A and 1B) were negative. Occa-
sionally, a few acinar cells showed weak cytoplasmic staining and
the islet cells generally displayed weak granular cytoplasmic
labelling (Figure 1F). All endocrine tumours of the pancreas lacked
cytoplasmic expression of ADAM9. This was also true of acinar cell
carcinomas, with the exception of two that showed weak
membranous staining in areas with dilated acinar structures, so-
called glandular formation.
ADAM9 expression and patient survival
We found no significant association between cytoplasmic ADAM9
staining and patient age or stage, whereas the tumour grade was
found to be statistically significant (P¼0.03, Fisher’s exact test;
Table 2). Similarly, no correlations between the intensity of
ADAM9 staining, luminal ADAM9 and basolateral ADAM9
expression and these clinicopathological parameters were ob-
tained. We also found no correlation between ADAM9 staining
intensity and the occurrence of cytoplasmic ADAM9 staining (data
not shown). For the univariate survival analyses, cumulative
survival curves were calculated according to the Kaplan–Meier
method. This analysis demonstrated statistical significance for the
following parameters: tumour grade and cytoplasmic and baso-
lateral ADAM9 expression (Figure 2, Table 3). The mean survival
time of patients with PDAC without cytoplasmic ADAM9
expression was 30 months (73; median 2874), compared to 16
months (72; median 1171) for those whose tumours showed
cytoplasmic ADAM9 expression (Po0.001, Table 3). The mean
survival time for patients with PDAC who showed no basolateral
ADAM9 staining was 40 months (76; median 3773), compared to
18 months (74; median 72) for those PDAC patients with
basolateral ADAM9 expression (Po0.001, Table 3).
A multivariate progression analysis based on the Cox propor-
tional hazard model was performed in order to test the
Figure 1 ADAM9 immunostaining in pancreatic tissues. Well-differentiated PDAC showing distinct apical ADAM9 staining at the luminal cell membrane
(A); PDAC with luminal and basolateral membranous ADAM9 staining (B); poorly differentiated PDAC with basolateral membranous and focally
accentuated cytoplasmic staining (arrow) (C, D); chronic pancreatitis with faint apical staining of the epithelium of a small duct (arrow) (E); normal
pancreatic tissue showing staining of the luminal cell membrane of centroacinar cells and intralobular duct cells and faint granular staining of the cytoplasm of
islet cells (arrow) (F).
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patients with R0 resection (N¼42). Only cytoplasmic expression
of ADAM9 and tumour grade were found to be independent
prognostic factors for poor overall survival (cytoplasmic ADAM9:
HR¼2.85; 95% CI: 1.21–6.71, Po0.05; tumour grade: HR¼4.81;
95% CI: 2.43–9.52; Po0.01) (Table 3).
DISCUSSION
ADAM9, a member of the ADAM family that is involved in various
biological processes (Moss et al, 2001), was found to be
overexpressed in prostate carcinoma cell lines, hepatocellular
carcinoma and breast carcinoma (McCulloch et al, 2000; Le Pabic
et al, 2003; O’Shea et al, 2003). In PDAC, we and others observed
ADAM9 overexpression by gene expression profiling. While
Iacobuzio-Donahue et al (2003) used cDNA microarray analysis,
with subsequent validation of the ADAM9 overexpression by RT–
PCR in PDAC cell lines, we based our examination on the use of
Affymetrix GeneChips and validated the distinct immunohisto-
chemical expression of ADAM9 in a small series of PDACs
(Grutzmann et al, 2003).
This study was designed to further validate the significance of
ADAM9 overexpression in PDACs by comparing the results with
Table 2 Relationship between cytoplasmic ADAM9 expression and various clinicopathological factors in all patients with pancreatic ductal
adenocarcinomas (PDAC)
Characteristic All cases Cytoplasmic ADAM9-negative Cytoplasmic ADAM9-positive Significance
All PDACs 59 (100%) 42 (71%) 17 (29%)
Age at surgery 0.15
a
o61 years 28 (48%) 17 (61%) 11 (39%)
461 years 31 (52%) 25 (80%) 6 (20%)
Histological grade
G2 33 (56%) 29 (88%) 4 (12%) 0.03
a
G3 26 (44%) 13 (50%) 13 (50%)
Tumour stage 0.38
b
pT1 1 (1,7%) 1 (100%)
pT2 6 (10%) 4 (67%) 2 (33%)
pT3 47 (80%) 35 (75%) 12 (25%)
pT4 5 (8.3%) 2 (40%) 3 (60%)
pN 0.78
a
pN0 23 (39%) 17 (74%) 6 (26%)
pN1 36 (61%) 25 (69%) 11 (31%)
pM 1.00
a
pM0 52 (88%) 37 (71%) 15 (29%)
pM1 7 (12%) 5 (71%) 2 (29%)
Residual tumour 0.75
a
R0 42 (71%) 29 (70%) 13 (30%)
R1 17 (29%) 13 (76%) 4 (24%)
UICC stage 0.3
b
I 3 (5%) 1 (33%) 2 (67%)
II 16 (27%) 13 (81%) 3 (19%)
III 25 (42%) 18 (72%) 7 (28%)
IV 12 (20%) 7 (58%) 5 (42%)
aFisher’s exact test.
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Figure 2 Kaplan–Meier curves of overall survival of PDAC patients showing different ADAM9 expression patterns (cyt: cytoplasmic; lat: basolateral).
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correlating the immunohistochemical labelling of the individual
PDACs with the survival of the patients.
ADAM9 was detected in 58 of 59 PDACs along the apical lumen-
oriented membrane of the neoplastic glandular structures.
In addition, 32 of the 59 PDACs showed staining of the basolateral
cell membrane and 17 revealed cytoplasmic positivity. In
the normal adjacent pancreatic tissue, ADAM9 staining, although
weak, was also detected at the luminal surface of the interlobular
ductal cells and centroacinar cells. It appears that ADAM9 is
preferentially a luminal membrane-bound protein of duct-type
pancreatic cells. As the apical membrane labelling, observed in
the adjacent normal pancreatic tissue, is preserved in almost all
PDACs, we might speculate that ADAM9 function could at
least partly be maintained in the tumour cells. Among the
pancreatic tumours, that is neoplasms of the acinar, endocrine
and ductal phenotype, ADAM9 expression was selective for
PDACs. Interestingly, endocrine neoplasms did not express
ADAM9, although the islet cells in the normal pancreas displayed
consistent granular cytoplasmic staining. These results indicate
that ADAM9 might not play a role in the biology of nonduct-type
neoplasms of the pancreas, but may be important for the biology of
PDACs.
The distribution pattern of ADAM9 in PDACs was related to the
differentiation of the individual tumours. More than two thirds of
the well and moderately differentiated PDACs showed only apical
membranous ADAM9 labelling, while poorly differentiated PDACs
usually exhibited additional basolateral membranous and cyto-
plasmic staining. Whether this change bestows a progression
advantage on the tumour cells is not yet known. However, because
we found that cytoplasmic and basolateral ADAM9 staining
correlates with poor survival in PDAC patients, it may be
speculated that this over-expression pattern of ADAM9 promotes
PDAC progression.
The relationship between the ADAM9 expression pattern in
PDAC and the survival probability was tested in a series of
curatively resected patients. This test, using a multivariate analysis,
revealed cytoplasmic expression of ADAM9 to be an independent
prognostic factor in patient survival. The second independent
factor detected by this analysis was tumour grade, confirming
earlier studies (Luttges et al, 2000). As there was a relationship
between differentiation and the ADAM9 expression pattern, the
possibility has to be considered that the two factors might be
interrelated.
So far the precise function of ADAM9 in the pancreas is
unknown. The designation ADAM is derived from their two
transmembrane domains, which possess A Disintegrin And a
Metalloprotease function (Izumi et al, 1998). The ADAMs
are a multifunctional gene family, some members of which
have been shown to play a role in diverse biological processes
such as fertilization, myogenesis, neurogenesis and the activation
of growth factors/immune regulators such as TNF-alpha.
Moreover, ADAM9 is known to cleave heparin-binding
EGF-like growth factor (Roghani et al, 1999). The disintegrin
function probably relates to cell-to-cell and cell-to-
extracellular matrix (ECM) adhesive interactions and transduction
of signals from the ECM to the cell interior and vice versa.
It may be involved in cell migration, invasion, intra- and
extravasation and platelet interaction (Poggi et al, 1993; Mize-
jewski, 1999).
If ADAM9 overexpression is involved in PDAC progression, it
may exert its action either via its disintegrin domain or its
metalloproteinase domain or, most likely, via both. Various matrix
metalloproteinases (MMP) like MMP2 and MMP9 have been
described as being overexpressed in PDACs and seem to play an
important role in the progression of PDAC (for a review cf.
Bloomston et al, 2002). These observations led to a clinical trial of
the metalloproteinase inhibitor marimastat in PDAC, which
provided evidence of a dose response (Bramhall et al, 2001).
Moreover, marimastat is potent not only against MMPs but also
against ADAM9 (Moss et al, 2001). It may therefore be speculated
that the response to marimastat in patients with PDAC may be in
part due to inhibition of ADAM9. If this proved true, ADAM9
might play a role in tumour progression, and might be used not
only for prognostic and diagnostic purposes but also for novel
therapeutic approaches. Misallocation of ADAM9 from the luminal
membrane to the cytoplasm and the basolateral membrane might
add to an activation of growth factors and the degradation of ECM
by ADAM9.
In conclusion, we have demonstrated that ADAM9 is over-
expressed in PDACs but not in endocrine tumours or acinar cell
carcinomas. Furthermore, we found a significant association
between cytoplasmic ADAM9 overexpression and survival in
patients curatively resected for PDAC. This suggests that
cytoplasmic ADAM9 overexpression may be a useful diagnostic
marker and could also become a potential target in the treatment
of PDAC.
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Table 3 Results of the univariate and multivariate analyses in patients with pancreatic ductal adenocarcinomas (PDAC)
HR (95% CI) P-value
Category No. dead/total (%) Univariate
a Multivariate
b Univariate Multivariate
Cytoplasmic ADAM9 expression
Negative 32/42 (76.2) 1 1 – –
Positive 15/17 (88.2) 3.94 (1.72 ... 9.05) 2.85 (1.21 ... 6.71) o0.001 o0.05
Laterobasal ADAM9 expression
Negative 12/21 (57.1) 1 – – –
Positive 30/32 (93.7) 3.49 (1.81 ... 6.73) – o0.001 –
Grade
1/2 21/33 (63.6) 1 1 – –
3 26/26 (100.0) 4.81 (2.43 ... 9.52) 3.34 (1.49 ... 7.47) o0.001 o0.01
aA total of 59 patients with PDAC.
bA total of 42 patients with curatively (R0) resected PDAC. HR¼hazard ratio.
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